Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
direct factor Xa inhibitor |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B01AF11
|
| gptkbp:brand |
gptkb:Bevyxxa
|
| gptkbp:CASNumber |
330942-05-7
|
| gptkbp:developedBy |
gptkb:Portola_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
19-27 hours
|
| gptkbp:hasMolecularFormula |
C23H22ClN5O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
betrixaban
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits factor Xa
|
| gptkbp:molecularWeight |
451.91 g/mol
|
| gptkbp:proteinBinding |
60%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
prevention of venous thromboembolism
|
| gptkbp:bfsParent |
gptkb:Factor_X
|
| gptkbp:bfsLayer |
6
|